Advancing Immunotherapy with Vision and World-class Expertise
Unlocking New Opportunities in Immunotherapy
Founded in Lausanne, Switzerland, MabQuest Therapeutics is dedicated to transforming the way we harness the immune response to fight life-threatening diseases. With in-depth expertise in immunology, virology, and oncology, our Leadership and Experts team is focused on addressing complex challenges in oncology, infectious diseases, and allergy through innovative immune modulation.
Our Vision is to overcome the current limits of conventional immune checkpoint inhibitors by leveraging the unique benefits of allosteric modulation—expanding cancer indications that can be treated and enhancing anti-tumor efficacy for underserved patient populations.
The Visionaries Behind MabQuest Therapeutics
At MabQuest Therapeutics, our team is our strength. We are guided by leaders with deep expertise in immunology, oncology, and clinical research, all dedicated to transforming cancer care. Their collective insights and strategic guidance drive MabQuest’s mission to pioneer transformative, allosteric immunotherapies—driving us to the forefront of immunotherapy medicines with a goal of delivering safer, more effective treatments for patients worldwide.
Dr. Giuseppe Pantaleo
Prof. Pantaleo is a world-renowned immunologist at Lausanne University Hospital, recognized for groundbreaking contributions to HIV/AIDS research, immunotherapy, immune activation, and T-cell exhaustion. He has authored over 400 publications and received numerous awards, including The National Institutes of Health Director Award, The National Institutes of Health Award of Merit, the Pfizer Research Prize in Clinical Research in Infectious Disease, The Foundation Prof. Dr. Max Cloetta Prize, The FBM University of Lausanne Translational Research Award, The FBM University of Lausanne Lifetime Achievement Award.
Dr. Craig Fenwick
Dr. Fenwick, a former Senior Principal Scientist and Project Leader at Boehringer Ingelheim R&D, leads the antibody discovery and immune-monitoring platforms at the Lausanne University Hospital. His expertise includes studying immune profiles associated with infectious diseases, cancer, and vaccine responses, with a strong background in cellular immunology, protein biophysical analysis, mechanistic studies, assay development and drug discovery.
Prof. John A. Thompson
Prof. Thompson is a leading expert in melanoma and kidney cancer, pioneering immunotherapy innovations involving lymphocytes and immune checkpoint inhibitors. He chaired the guidelines committee for management of immunotherapy-related toxicities for the National Comprehensive Cancer Center and participated in similar efforts for ASCO and SITC.
Ms. Song Ding
Song Ding has an extensive background in translational clinical research, operations, and management of multi-center clinical trials in Europe, USA and Africa. She has overseen and contributed to the implementation and management of nearly 20 Phase I/II vaccine and antibody trials, with the focus on regulatory affairs and product management.
Claude Ramoni
Claude Ramoni is a founding partner of the Lausanne-based law firm Libra Law. With over two decades of experience, he notably advises and represents clients in their business activities, in particular companies and entities active in scientific research and health care. In addition to his practice, he serves on boards of various companies and foundations and lectures at institutions such as the University of Lausanne.
Steering Our Future with Expert Guidance
Our advisory board comprises some of the most respected figures in oncology and immunotherapy:
Prof. Christophe Massard
Prof. Massard heads the Department of Therapeutic Innovation and Early Clinical Trials (DITEP) at Gustave Roussy in Paris. He specializes in genitourinary and central nervous system tumors, focusing on personalized therapies targeting tumor-specific genetic profiles. His work includes leading programs like MOSCATO, MATCH-R, and PETRUS.
Dr. Jim Tartaglia
Dr. Jim Tartaglia is a seasoned development leader with over 30 years of industry experience. He has held prominent roles at Sanofi and previously served as Executive Director of Research at Virogenetics Corporation in Troy, New York. Dr. Tartaglia holds a Ph.D. in Microbiology and Immunology, has authored over 130 publications, and is credited with more than 20 patents.
Prof. Solange Peters
Prof. Peters is Chief of Medical Oncology at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland. She specializes in thoracic malignancies, including lung and pleural cancers, with a focus on immunotherapy and biomarker discovery. A prolific author, she served as President of the European Society for Medical Oncology (ESMO) from 2020 to 2022.
Prof. Arlene Sharpe
Prof. Sharpe’s pioneering work on the PD-1 immune checkpoint pathway has revolutionized cancer immunotherapy, enabling life-changing treatments like checkpoint inhibitors. Recognized globally, Dr. Sharpe's research on T-cell regulation and immune evasion has positioned her as a driving force in advancing immunology and cancer therapies.
Prof. Rafick-Pierre Sekaly
Prof. Sekaly is Vice-Chair of Translational Medicine in the Department of Pathology and Laboratory Medicine at Emory University School of Medicine in Atlanta, Georgia. He has pioneered the use of transcriptomics and bioinformatics to identify predictors/correlates of immune responses that lead to protection from viral infections, disease progression and licensed preventative and therapeutic vaccines.